Animal models of cardiac cachexia

Francesca Molinari, Natalia Malara, Vincenzo Mollace, Giuseppe Rosano, Elisabetta Ferraro

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Cachexia is the loss of body weight associated with several chronic diseases including chronic heart failure (CHF). The cachectic condition is mainly due to loss of skeletal muscle mass and adipose tissue depletion. The majority of experimental in vivo studies on cachexia rely on animal models of cancer cachexia while a reliable and appropriate model for cardiac cachexia has not yet been established. A critical issue in generating a cardiac cachexia model is that genetic modifications or pharmacological treatments impairing the heart functionality and used to obtain the heart failure model might likely impair the skeletal muscle, this also being a striated muscle and sharing with the myocardium several molecular and physiological mechanisms. On the other hand, often, the induction of heart damage in the several existing models of heart failure does not necessarily lead to skeletal muscle loss and cachexia. Here we describe the main features of cardiac cachexia and illustrate some animal models proposed for cardiac cachexia studies; they include the genetic calsequestrin and Dahl salt-sensitive models, the monocrotaline model and the surgical models obtained by left anterior descending (LAD) ligation, transverse aortic constriction (TAC) and ascending aortic banding. The availability of a specific animal model for cardiac cachexia is a crucial issue since, besides the common aspects of cachexia in the different syndromes, each disease has some peculiarities in its etiology and pathophysiology leading to cachexia. Such peculiarities need to be unraveled in order to find new targets for effective therapies.

Original languageEnglish
Pages (from-to)105-110
Number of pages6
JournalInternational Journal of Cardiology
Volume219
DOIs
Publication statusPublished - Sep 15 2016

Fingerprint

Cachexia
Animal Models
Skeletal Muscle
Heart Failure
Calsequestrin
Monocrotaline
Anatomic Models
Striated Muscle
Genetic Models
Constriction
Ligation
Adipose Tissue
Myocardium
Chronic Disease
Salts
Body Weight
Pharmacology

Keywords

  • Atrophy
  • Heart failure
  • Preclinical
  • Rehabilitation
  • Skeletal muscle

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Animal models of cardiac cachexia. / Molinari, Francesca; Malara, Natalia; Mollace, Vincenzo; Rosano, Giuseppe; Ferraro, Elisabetta.

In: International Journal of Cardiology, Vol. 219, 15.09.2016, p. 105-110.

Research output: Contribution to journalArticle

Molinari, Francesca ; Malara, Natalia ; Mollace, Vincenzo ; Rosano, Giuseppe ; Ferraro, Elisabetta. / Animal models of cardiac cachexia. In: International Journal of Cardiology. 2016 ; Vol. 219. pp. 105-110.
@article{4a93cf6b71a648c38f4235d0bd38b2e1,
title = "Animal models of cardiac cachexia",
abstract = "Cachexia is the loss of body weight associated with several chronic diseases including chronic heart failure (CHF). The cachectic condition is mainly due to loss of skeletal muscle mass and adipose tissue depletion. The majority of experimental in vivo studies on cachexia rely on animal models of cancer cachexia while a reliable and appropriate model for cardiac cachexia has not yet been established. A critical issue in generating a cardiac cachexia model is that genetic modifications or pharmacological treatments impairing the heart functionality and used to obtain the heart failure model might likely impair the skeletal muscle, this also being a striated muscle and sharing with the myocardium several molecular and physiological mechanisms. On the other hand, often, the induction of heart damage in the several existing models of heart failure does not necessarily lead to skeletal muscle loss and cachexia. Here we describe the main features of cardiac cachexia and illustrate some animal models proposed for cardiac cachexia studies; they include the genetic calsequestrin and Dahl salt-sensitive models, the monocrotaline model and the surgical models obtained by left anterior descending (LAD) ligation, transverse aortic constriction (TAC) and ascending aortic banding. The availability of a specific animal model for cardiac cachexia is a crucial issue since, besides the common aspects of cachexia in the different syndromes, each disease has some peculiarities in its etiology and pathophysiology leading to cachexia. Such peculiarities need to be unraveled in order to find new targets for effective therapies.",
keywords = "Atrophy, Heart failure, Preclinical, Rehabilitation, Skeletal muscle",
author = "Francesca Molinari and Natalia Malara and Vincenzo Mollace and Giuseppe Rosano and Elisabetta Ferraro",
year = "2016",
month = "9",
day = "15",
doi = "10.1016/j.ijcard.2016.05.071",
language = "English",
volume = "219",
pages = "105--110",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Animal models of cardiac cachexia

AU - Molinari, Francesca

AU - Malara, Natalia

AU - Mollace, Vincenzo

AU - Rosano, Giuseppe

AU - Ferraro, Elisabetta

PY - 2016/9/15

Y1 - 2016/9/15

N2 - Cachexia is the loss of body weight associated with several chronic diseases including chronic heart failure (CHF). The cachectic condition is mainly due to loss of skeletal muscle mass and adipose tissue depletion. The majority of experimental in vivo studies on cachexia rely on animal models of cancer cachexia while a reliable and appropriate model for cardiac cachexia has not yet been established. A critical issue in generating a cardiac cachexia model is that genetic modifications or pharmacological treatments impairing the heart functionality and used to obtain the heart failure model might likely impair the skeletal muscle, this also being a striated muscle and sharing with the myocardium several molecular and physiological mechanisms. On the other hand, often, the induction of heart damage in the several existing models of heart failure does not necessarily lead to skeletal muscle loss and cachexia. Here we describe the main features of cardiac cachexia and illustrate some animal models proposed for cardiac cachexia studies; they include the genetic calsequestrin and Dahl salt-sensitive models, the monocrotaline model and the surgical models obtained by left anterior descending (LAD) ligation, transverse aortic constriction (TAC) and ascending aortic banding. The availability of a specific animal model for cardiac cachexia is a crucial issue since, besides the common aspects of cachexia in the different syndromes, each disease has some peculiarities in its etiology and pathophysiology leading to cachexia. Such peculiarities need to be unraveled in order to find new targets for effective therapies.

AB - Cachexia is the loss of body weight associated with several chronic diseases including chronic heart failure (CHF). The cachectic condition is mainly due to loss of skeletal muscle mass and adipose tissue depletion. The majority of experimental in vivo studies on cachexia rely on animal models of cancer cachexia while a reliable and appropriate model for cardiac cachexia has not yet been established. A critical issue in generating a cardiac cachexia model is that genetic modifications or pharmacological treatments impairing the heart functionality and used to obtain the heart failure model might likely impair the skeletal muscle, this also being a striated muscle and sharing with the myocardium several molecular and physiological mechanisms. On the other hand, often, the induction of heart damage in the several existing models of heart failure does not necessarily lead to skeletal muscle loss and cachexia. Here we describe the main features of cardiac cachexia and illustrate some animal models proposed for cardiac cachexia studies; they include the genetic calsequestrin and Dahl salt-sensitive models, the monocrotaline model and the surgical models obtained by left anterior descending (LAD) ligation, transverse aortic constriction (TAC) and ascending aortic banding. The availability of a specific animal model for cardiac cachexia is a crucial issue since, besides the common aspects of cachexia in the different syndromes, each disease has some peculiarities in its etiology and pathophysiology leading to cachexia. Such peculiarities need to be unraveled in order to find new targets for effective therapies.

KW - Atrophy

KW - Heart failure

KW - Preclinical

KW - Rehabilitation

KW - Skeletal muscle

UR - http://www.scopus.com/inward/record.url?scp=84974661292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84974661292&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2016.05.071

DO - 10.1016/j.ijcard.2016.05.071

M3 - Article

VL - 219

SP - 105

EP - 110

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

ER -